Eye Diseases Clinical Trial
Official title:
Evaluation and Treatment of Pediatric, Developmental and Genetic Eye Diseases
This study will evaluate and treat children or adults with inherited or developmental eye
conditions. It will allow specialists in pediatric ophthalmology, genetic ophthalmology, and
ocular motility at the National Eye Institute (NEI) to learn more about the course of various
pediatric, genetic, developmental, and eye movement diseases thorough long-term observation
and treatment. It will also serve as the first step in determining the eligibility of
patients who may wish to enroll in other NEI clinical research studies or undergo standard
eye treatments.
Children with eye conditions, especially inherited or developmental conditions, and adults
with eye disorders that began in childhood or that likely have a genetic or developmental
component may be eligible for this study. Participants will undergo some or all of the
following procedures:
- Medical history, including family history.
- Physical examination and possibly routine blood tests, x-rays tests, standard eye
movement recordings, questionnaires, and specialized procedures when needed.
- Complete eye examination, including vision test, visual perception, eye pressure (if
possible), dilation of the pupils to examine the back of the eye (lens, vitreous, and
retina).
- Photographs of the eyes.
- Oculography (eye movement recordings) in patients for whom testing will aid in
diagnosis. This test is done either with goggles placed over the eyes or with a contact
lens placed on each eye. When the goggles or lenses are in place, the subject looks at a
series of red targets on a computer screen.
- Electroretinography (ERG) in patients with suspected retinal degeneration. This is a
test of the electrical function of the eyes. Before the test, patients sit in a dark
room for 30 minutes with their eyes patched. A small electrode (silver disk) is taped to
their forehead. The eye patches are then removed, the eyes are numbed with drops, and
contact lenses are placed in the eyes. The contact lenses sense small electrical signals
generated by the retina when lights flash. During the ERG recording, the patient looks
inside a large empty bowl. A light flashes, first in the dark and then with a light
turned on inside the bowl. The test takes 1 hour or less.
Participants are followed up to 6 times a year for 3 years, depending on the diagnosis and
treatment.
The purpose of this protocol is to allow the pediatric ophthalmology, genetic ophthalmology,
and ocular motility specialists at the National Eye Institute to gain additional knowledge of
the course of various pediatric, genetic, developmental and ocular motility diseases.
Heretofore, this spectrum of diseases will be referred to as pediatric ophthalmology
diseases. We wish to evaluate the effects of standard treatments for these diseases, use non-
or minimally-invasive technologies to understand the pathogenesis of these diseases, and to
collect blood or other easily obtained biologic sample (e.g., urine, saliva, hair, cheek
swab, or stool) for future laboratory studies on these diseases. The information gained from
this protocol will also allow for the maintenance of populations of patients with specific
pediatric eye diseases and strabismus that may be eligible for future protocols. In addition,
by allowing for the care of patients with a spectrum of these diseases, the protocol will be
valuable for the training of pediatric eye disease, ocular genetics, and ocular motility
fellows. The pediatric, genetic, and eye movement specialists at the National Eye Institute
will choose ophthalmology diseases based on the training and research needs of the NEI
program. While the primary focus of this protocol is to study eye disease in children, adults
who have a disease that began in childhood or who may have an inherited eye disease or are
unaffected first-degree relatives may also be evaluated under this protocol.
This protocol is not designed to test any new treatments. Any evaluation of treatments under
this protocol will be based on the standard-of-care for each patient's disease. All
alternatives for evaluation and care will be reviewed with each patient and the patient's
family.
Patients in this evaluation and treatment protocol will be evaluated for potential
eligibility in any new NEI clinical trials or epidemiological protocols as they are
developed. If eligible, patients may be asked to participate in a new protocol. However, they
will not be required to enter any new protocol and their decision to participate will be
entirely voluntary.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05414994 -
Assessment of the Ocular Microbiome in Health and Disease
|
||
| Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
| Completed |
NCT02811692 -
Study for Collection of Aflibercept Data in Routine Practice
|
||
| Recruiting |
NCT06045299 -
Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia
|
Phase 3 | |
| Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
| Completed |
NCT04799704 -
Tear Film SARS-nCoV-2 Detection in Symptomatic and Pauci-symptomatic Patients.
|
||
| Recruiting |
NCT05876689 -
Swept Source OCT Imaging With the DREAM VG-OCT
|
||
| Active, not recruiting |
NCT04123626 -
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04150432 -
Correlation Between Exhaled Propofol Concentration With Plasma Concentration in Children
|
N/A | |
| Not yet recruiting |
NCT05550740 -
Repeated Low-Level Red-Light Therapy for Shortening Axial Length
|
N/A | |
| Completed |
NCT02332343 -
Sparing of the Fovea in Geographic Atrophy Progression
|
N/A | |
| Completed |
NCT01727973 -
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
|
Phase 1/Phase 2 | |
| Terminated |
NCT01225146 -
Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
|
Phase 1 | |
| Completed |
NCT00333203 -
Next Generation Ophthalmic Irrigating Solution Posterior Segment Study
|
Phase 3 | |
| Not yet recruiting |
NCT05565547 -
Multimodal Equipment for Teleophthalmology Assessment (META)
|
||
| Recruiting |
NCT05158699 -
Effectiveness of Periocular Drug Injection in CATaract Surgery
|
Phase 3 | |
| Recruiting |
NCT06451172 -
Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis
|
Early Phase 1 | |
| Recruiting |
NCT06112340 -
A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
|
Phase 2/Phase 3 | |
| Completed |
NCT05211089 -
Manual Versus Automated Choroidal Thickness Measurements Using Swept-source Anterior Segment OCT
|
||
| Not yet recruiting |
NCT06070467 -
Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases
|